Discover
PVLA
Palvella Therapeutics, Inc.
138.77
2 x 111.17
2 x 195.41
bid
ask
+
7.43
5.66%
2 @ 04:00 PM
138.77 +0.00 (0.00%)
| Ytd | 32.58% | |
| 1y | 97.99% |
128.80
day range
139.81
69.90
52 week range
158.13
| Open | 130.70 | Prev Close | 131.34 | Low | 128.80 | High | 139.81 | Mkt Cap | 2.00B |
| Vol | 174.04K | Avg Vol | 211.36K | EPS | -5.12 | P/E | N/A | Forward P/E | -18.51 |
| Beta | -0.27 | Short Ratio | 11.81 | Inst. Own | 103.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 147.85 | 200-d Avg | 124.44 | 1yr Est | 230.53 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-10 | 2026-09 | -1.8 | N/A | N/A | N/A |
| 2026-08-04 | 2026-06 | -1.17 | -1.52 | -0.35 | -29.91% |
| 2026-05-07 | 2026-03 | -0.9 | -1.2 | -0.3 | -33.33% |
| 2026-03-31 | 2025-12 | -0.91 | -1.08 | -0.17 | -18.53% |
| 2025-11-11 | 2025-09 | -0.85 | -1.03 | -0.18 | -21.18% |
| 2025-08-14 | 2025-06 | -0.78 | -0.86 | -0.08 | -10.26% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-21 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-21 | Stephens & Co. | Upgrade | Overweight | Overweight |
| 2026-05-21 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-05-12 | Stephens & Co. | Upgrade | Overweight | |
| 2026-03-31 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-03-24 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-08-18 | GOIN KATHLEEN | Chief Operating Officer | 0.00 | Conversion of Exercise of derivative security |
| 2026-02-26 | HERON ELAINE J | Director | 53.69K | Purchase |
| 2026-09-14 | JENKINS GEORGE M | Director | 173.63K | Sale |
| 2026-09-01 | KIRITSY CHRISTOPHER P | Director | 250.00 | Conversion of Exercise of derivative security |
| 2026-06-11 | KORENBERG MATTHEW E | Chief Financial Officer | 1000 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Montanova Capital LLC | 1.14M | 157.56M | 7.88% |
| 2026-06-29 | Jennison Associates LLC | 960.62K | 133.31M | 6.67% |
| 2026-06-29 | Blackrock Inc. | 918.36K | 127.44M | 6.37% |
| 2026-06-29 | Frazier Life Sciences Management, L.P. | 882.40K | 122.45M | 6.12% |
| 2026-06-29 | First Light Asset Management, LLC | 771.90K | 107.12M | 5.36% |
| 2026-06-29 | BVF Inc. | 672.79K | 93.36M | 4.67% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-08-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 431.53K | 59.88M | 2.99% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 388.39K | 53.90M | 2.70% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 279.12K | 38.73M | 1.94% |
| 2026-07-30 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 276.56K | 38.38M | 1.92% |
| 2026-06-29 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 231.48K | 32.12M | 1.61% |
| 2026-07-30 | PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 209.83K | 29.12M | 1.46% |